Evidence map›Paper›PMID 42505366›Full record

ArticleCells2026

Cytoskeletal Protein 4.1R Inhibits BCR-Mediated B-Cell Activation by Restraining AKT1 Phosphorylation.

Yuying Guo, Dandan Fan, Denghui Liu, Qi Shao, Siyao Sang, Yuting Niu, Lixiang Chen, Taotao Liang

Abstract read
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuying GuoSchool of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, China.ORCID 0009-0009-3860-3433
Dandan FanSchool of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, China.ORCID 0000-0003-0644-0173
Denghui LiuDepartment of Forensic Science and Technology, Zhengzhou Police University, Zhengzhou 450053, China.
Qi ShaoSchool of Pharmaceutical Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, China.
Siyao SangSchool of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, China.
Yuting NiuSchool of Basic Medical Sciences, Zhongzhou Laboratory, Henan University, Kaifeng 475004, China.
Lixiang ChenSchool of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, China.ORCID 0000-0001-7785-2496
Taotao LiangSchool of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, China.ORCID 0000-0002-2152-4861

Funding

Henan Province Medical Science and Technology Talents Overseas Training Program H20240012Henan Province Traditional Chinese Medicine Science and Technology Research Special Project 2024ZY2142National Natural Science Foundation of China 81571526National Natural Science Foundation of China 82200222
6 · The paper itself

Abstract

B-cell receptor (BCR) is indispensable for B-cell responses, and its signaling relies on the rearrangement of cytoskeletal proteins. Cytoskeletal protein 4.1R has been previously implicated in the regulation of immune function. However, the specific role of 4.1R in BCR-mediated B-cell activation remains unknown. Here, we performed single-cell RNA (scRNA) sequencing on splenic B cells isolated from wild-type (WT) and 4.1R-knockout (4.1R-KO) mice to systematically characterize the functional contribution of 4.1R to B-cell biology. Transcriptomic analyses suggested a critical role for 4.1R in modulating BCR signaling. Ex vivo stimulation of primary B cells with anti-IgM demonstrated that 4.1R-KO B cells exhibited marked overactivation, hyperproliferation, and enhanced antibody secretion. Furthermore, unbiased phosphoproteomic profiling, identified sustained AKT1 phosphorylation as a key feature in 4.1R-KO B cells. Subsequent functional validation confirmed that 4.1R regulates BCR signaling by constraining AKT1 activation. Mechanistically, 4.1R rapidly colocalized with the coreceptor CD19 at the plasma membrane upon BCR engagement, and co-immunoprecipitation confirmed their physical interaction. Loss of 4.1R disrupted this interaction and resulted in sustained and amplified AKT1 phosphorylation (but not AKT2) in stimulated B cells. Collectively, our findings identify 4.1R as a novel negative regulator of BCR signaling that interacts with CD19 to constrain AKT1 activation.

Indexed as

B-LymphocytesCytoskeletal ProteinsLymphocyte ActivationMicrofilament ProteinsProto-Oncogene Proteins c-aktReceptors, Antigen, B-CellAnimalsAntigens, CD19Membrane ProteinsMiceMice, Inbred C57BLMice, KnockoutPhosphorylationSignal TransductionAkt1 protein, mouseAntigens, CD19Cytoskeletal ProteinsEpb41 protein, mouseMembrane ProteinsMicrofilament ProteinsProto-Oncogene Proteins c-aktReceptors, Antigen, B-CellAKT1 phosphorylationB-cell activationBCR signalingprotein 4.1R

Identifiers

PMID42505366
PMCPMC13406958

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.